AKT1 and in situ carcinoma: With regard to the cancer cells, the treatment with 10 μM and 20 μM CIS showed no aberrant activation of AKT at the serine residue 473 in A549 (Fig. 5a), SAS (Fig. 5b) and SKOV-3 cells (Fig. 5c) compared to the control cells.